Lapas attēli
PDF
ePub

Statement of-Continued

Bain, James A., Ph. D., director, Division of Basic Health Sciences, Page Emory University.

Brennan, Bruce J., vice president and general counsel, Pharmaceutical
Manufacturers Association____

449

461

Brill, Dr. Henry, chairman, Committee on Alcoholism and Drug
Dependence, Council on Mental Health, American Medical Asso-
ciation.
Chayet, Neil L., lecturer in legal medicine at the Boston University
School of Law, Boston University School of Medicine, Tufts
University School of Medicine, and Tufts University School of
Dental Medicine___

Cole, Dr. Jonathan O., chairman, Committee for Effective Drug
Abuse Legislation, and in behalf of the American College of
Neuro-Psycho Pharmacology-

Corman, Hon. James C., a Representative in Congress from the
State of California..

231

275

310

65

David, Clifford C., legislative counsel, Smith Kline & French Laboratories_.

de la Garza, Hon. Kika, a Representative in Congress from the State of Texas.

Dean, John W., III, Associate Deputy Attorney General, Department of Justice...

Denney, Hon. Robert V., a Representative in Congress from the State
of Nebraska... -

Dobbs, Dr. Dorothy, Director, Marketed Drugs Division, Bureau of
Drugs, Food and Drug Administration, Public Health, Service,
Department of Health, Education, and Welfare..

264

215

79

665

340, 493

Egeberg, Dr. Roger O., Assistant Secretary for Health and Scientific
Affairs, Department of Health, Education, and Welfare
Ellenbogen, Theodore, Assistant General Counsel for Legislation,
Department of Health, Education, and Welfare____

171

171, 340

Farabee, Dr. Dale, secretary, National Association of State Mental
Health Program Directors..

Farnsworth, Dana L., director, University Health Services, Harvard
University-

Fletcher, Donald K., manager of distribution protection, Smith
Kline & French Laboratories__.

Freedman, Dr. Daniel X., professor and chairman, Department of
Psychiatry, University of Chicago, in behalf of American Psychiat-
ric Association_

518

549

264

419, 429

Freeland, Michael E., associate director, National Association for
Mental Health, Inc..

Gallagher, Hon. Cornelius E., a Representative in Congress from the
State of New Jersey-

Giaimo, Hon. Robert N., a Representative in Congress from the State
of Connecticut_.

Gibson, Dr. Merle, Director, New Drugs Division, Bureau of Drugs,
Food and Drug Administration, Public Health Service, Department
of Health, Education, and Welfare..........

Goddard, Dr. James L., on behalf of the American Public Health
Association_.

Goodrich, William, General Counsel, Bureau of Drugs, Food and
Drug Administration, Public Health Service, Department of
Health, Education, and Welfare..

295

516

205

340

255

340, 493

Griffith, Dr. John D., assistant professor, Psychiatry and Pharma-
cology, Vanderbilt University School of Medicine....

Griffiths, Hon. Martha W., a Representative in Congress from the
State of Michigan__

455

659

Hanna, Hon. Richard T., a Representative in Congress from the State of California_.

208

Ingersoll, John E., Director, Bureau of Narcotics and Dangerous
Drugs, Department of Justice._.

Hunt, Hon. John E., a Representative in Congress from the State of
New Jersey.

329

79, 82, 675

Jaffe, Dr. Jerome H., associate professor of psychiatry, University of
Chicago---

320

Statement of-Continued

Jennings, Dr. John, Acting Director, Bureau of Drugs, Food and Drug Administration, Public Health Service, Department of Health, Education, and Welfare.

Page

340, 493

Johnson, Hon. Harold T. (Bizz), a Representative in Congress from
the State of California

Klein, Dr. Donald F., director of research, Hillside Hospital, Glen
Oaks, N.Y....

Kline, Dr. Nathan S., New York, N. Y...

Lewis, Dr. Edward, Chief Medical Officer, Bureau of Narcotics and
Dangerous Drugs, Department of Justice..

Lipton, Dr. Morris A., professor and chairman, Department of Psy-
chiatry, University of North Carolina School of Medicine..
Lowinger, Dr. Paul, Council of Health Organizations---
Mahaffey, Fred T., executive director, National Association of Boards
of Pharmacy--

Mark, Ralph and Frances, Poughkeepsie, N. Y.

Meyer, Dr. Roger, School of Medicine, Boston University, former chief, Center for Studies of Narcotics and Drug Abuse, National Institute of Mental Health___

64

575

386

79, 675

447

524

666

482

556

Mikva, Hon. Abner J., a Representative in Congress from the State of
Illinois_-

287

Miller, Dr. Morton G., Associate Director for Special and Collabora-
tive Programs, National Institute of Mental Health, Department of
Health, Education, and Welfare. -

Mink, Hon. Patsy T., a Representative in Congress from the State of
Hawaii__

Mitchell, Hon. John N., Attorney General, Department of Justice,
as presented by John W. Dean III, Associate Deputy Attorney
General for Legislation...

171

216

79

419, 437

Moss, Sanford, in behalf of American Psychiatric Association..
Nix, Hon. Robert N. C., a Representative in Congress from the State
Pennsylvania_

Patton, William D., assistant general counsel, Pharmaceutical Manu-
facturers Association___

661

461

Pepper, Hon. Claude, a Representative in Congress from the State of
Florida_

579

Peterson, Harry N., attorney, legislative department, American
Medical Association_.

231

Pettis, Hon. Jerry L., a Representative in Congress from the State of
California__.

226

Podell, Hon. Bertram L., a Representative in Congress from the State of New York__

77

357

Roberts, Carl, director, legal division, American Pharmaceutical
Association__.

Schnibbe, Harry C., executive director, National Association of State
Mental Health Program Directors_

Schuster, Charles R., Ph. D., associate professor of psychiatry and
pharmacology, University of Chicago, and director of basic research,
State of Illinois Narcotic and Drug Abuse Program___
Sonnenreich, Michael R., Deputy Chief Counsel, Bureau of Narcotics
and Dangerous Drugs, Department of Justice__

Speiser, Lawrence, director, Washington (D.C.) Office, American Civil
Liberties Union_.

Stoddard, Ezekial G., special counsel, Pharmaceutical Manufacturers
Association.

518

568

79, 675

297

461

Thompson, Hon. Frank, Jr., a Representative in Congress from the
State of New Jersey-

74

Van Deerlin, Hon. Lionel, a Representative in Congress from the State of California__

62

Vigorito, Hon. Joseph P., a Representative in Congress from the State of Pennsylvania__

76

Waldie, Hon. Jerome R., a Representative in Congress from the State of California__.

662

West, Dr. Louis Jolyon, trustee, American Psychiatric Association. -Wilson, Hon. Charles H., a Representative in Congress from the State of California....

419

68

Statement of-Continued

Woods, William E., Washington representative, National Association
of Retail Druggists---

Wright, Mrs. J. Skelly, secretary, National Association for Mental
Health, Inc.___

Yolles, Dr. Stanley F., Director, National Institute of Mental Health,
Department of Health, Education, and Welfare.
Additional material submitted for the record by-
Abbott Laboratories, statement_-_

Page

411

295

171, 174

American Academy of Pediatrics, Robert G. Frazier, M.D., executive director, letter dated August 22, 1969, to Chairman Staggers--American Legion, Herald E. Stringer, director, Legislative Commission, letter dated March 4, 1970, to Chairman Jarman_ American Medical Association, letter date April 2, 1970, from Roy S. Bredder, legislative attorney, to Mr. Ed Williamson, clerk, House Interstate and Foreign Commerce Committee, re percentage of prescriptions a physician writes each day for tranquilizers, and including article entitled, "The nature and extent of psychotropic drug usage in the United States".

American Pharmaceutical Association:

Changes suggested in H.R. 13743, "The Controlled Depressant
and Stimulant Drugs Act of 1969".

Letter dated March 11, 1960, to Chairman Jarman re present
regulations of the BNDD of the Department of Justice regulat-
ing sale of exempt narcotic preparations; and information
which might reflect the extent to which pharmacists are in-
volved in illegal diversion or dispensing of drugs...
"Pharmacognosy and Chemistry of 'Canabis sativa'", by Norman
R. Farnsworth__

American Psychiatric Association:

Barton, Walter E., M.D., medical director, letter dated June 16,
1969, to Chairman Staggers__

752

811

828

241

364

383

367

810

Curriculum vitae-Daniel X. Freedman, M.D..

436

Position paper on drug abuse and the need to separate medical
research and practice from law enforcement in combating it. ---
Press release dated February 13, 1970-Committee For Effective
Drug Abuse Legislation, Washington, D.C..-

425

426

541

Ayd, Dr. Frank J., Jr., biographical sketch_
Bolter, Sidney, M.D., Detroit, Mich., letter dated February 20, 1970,
to Congressman Broomfield of Michigan, with forwarding letter to
Chairman Staggers-

831

Burks, Thomas F., Ph. D., assistant professor, School of Medicine,
Department of Pharmacology, University of New Mexico, letter
dated March 30, 1970, to Chairman Staggers-
Colorado Department of Health, Roy L. Cleere, M.D., M.P.H.,
executive director, letter dated March 17, 1970, to Subcommittee on
Public Health and Welfare, House Interstate and Foreign Commerce
Committee_

849

751

Council of Health Organizations:

Article from New York Times entitled "3 Health Groups Combine
To Fight 'Commercialized Medicine' ".

528

Biographical sketch: Paul Lowinger, M.D.

525

Extract from the proceedings of the Council of Health Organiza-
tions on February 15, 1969, meeting in New York City...
References to medical literature re effects of marihuana in

531

527

man_.

Daniel, Hon. Price, former U.S. Senator and Governor of Texas, statement with "The Illicit Narcotics Traffic," Senate Report No. 1440, dated January 23, 1956, attached..

731

De Jong, Jacob, M.D., psychiatrist, Newtown, Conn., letter dated
April 6, 1970, to Chairman Staggers, with attached paper entitled
"Efficacy of Phenothiazines Without Antiparkinson Drugs".
Dodd, Hon. Thomas J., a U.S. Senator from the State of Connecticut,
statement_.

832

726

Eli Lilly & Co., H. F. DeBoest, vice president, corporate affairs, statement

756

Additional material submitted for the record by-Continued

Ferraro, Douglas P., Ph. D., associate professor, Department of Psychology, University of New Mexico, letter dated March 11, 1970, to Congressman Manuel Lujan of New Mexico, with forwarding letter__

Hanna, Hon. Richard T., a Representative in Congress from the State
of California:

Article from the Santa Ana (Calif.) Register entitled "No Knock
on the Door".

Article from the Los Angeles (Calif.) Times entitled "No-Knock'
and Basic Rights".

Health, Education, and Welfare Department:

Characteristics of amphetamine drug dependence..
Fact and fable chart on marihuana__

Letter dated March 3, 1970, from Secretary Finch to Chairman
Jarman re favorable consideration of the administration's
proposed bill__

Letter dated March 30, 1970, from Dr. Roger O. Egeberg, to
Congressman Rogers re provisions of H.R. 13743 pertaining to
the responsibilities of the Secretary of HEW and the Attorney
General concerning the classification of dangerous drugs and
the enforcement of measures intended to regulate their produc-
tion, distribution, and use_.

Letter dated April 30, 1970, from M. J. Ryan, Acting Director,
Office of Legislative Services, to Chairman Jarman re additional
information on amphetamines..

Status of feneluramine__

Usefulness of amphetamines in epilepsy..

Usefulness of amphetamines in hospitalized psychopaths-Hoffman-La Roche Inc., Dr. V. D. Mattia, president and chief executive officer:

Supplemental statement.

Statement.

Hollister, Leo E., M.D., associate chief of staff, Veterans' Administration Hospital, Palo Alto, Calif., statement.

Page

848

214

214

501

180

705

202

507

505

496

496

767

776

747

Hunt, Hon. John E., a Representative in Congress from the State of New Jersey, condensed excerpts of testimony of John E. Ingersoll, Director, Bureau of Narcotics and Dangerous Drugs, on the subject of drug abuse S. 3246_

Institute of Living, Research Laboratories, Bernard C. Glueck, Jr., M.D., director of research, letter dated February 2, 1970, to Chairman Staggers_

Irwin, Samuel, Ph. D., professor of pharmacology, Department of Psychiatry, University of Oregon Medical School, letter dated February 19, 1970, to Mr. W. E. Williamson, clerk, House Committee on Interstate and Foreign Commerce, with attached papers entitled "Controlled Dangerous Substances Act" and "Drugs of Abuse: Their Actions and Relative Hazard Potential".

Justice Department:

332

811

836

Actual case which points out the need for agents to have the
ability to procure advanced "no-knock" authority prior to
executing a search warrant

125

Alternative penalties.

90

Depressant and stumulant drugs; proposed listing of additional
drugs subject to control..

683

Diversion analysis-BNDD..

724

Drug arrests-1969_-.

723

Estimated additional costs to the Bureau of Narcotics and
Dangerous Drugs to implement and administer the proposed
Controlled Dangerous Substances Act_-

147

Estimated registration fees---.

720

715

Justification for placement of alphacetylmethadol in schedule I
of the Controlled Dangerous Substances Act, S. 3246.
Letter dated February 3, 1970, from John N. Mitchell, Attorney
General, to Chairman Jarman re his being unable to appear
before the subcommittee__.

Members of the Scientific Advisory Committee on Drugs-
"No-Knock and Non-Sense: An Alleged Constitutional Problem.
Research project information-fiscal years 1969, 1970, and 1971--

92

154

106

95

Additional material submitted for the record by-Continued

White House Interdepartmental Committee on Drug Use and
Abuse__

Why no performance bonds are required under section 602b---
Kline, Dr. Nathan S.:
Curriculum vitae..

"Introduction-The Psychology, Philosophy, Mortality and
Legislative Control of Drug Usage”.

Number of resident patients in State and local government mental
hospitals in the United States (based on USPHS figures)–
1946-1968__

"The Successful Treatment of Narcotic Addiction With Anti-
depressants"
Mexican American Betterment Organization, Remigio Valdez, Jr.,
president, letter dated March 30, 1970, to Representative Patsy T.
Mink with forwarding letter to Chairman Jarman__
Mikuriya, Tod H., M.D., letter dated February 17, 1970, to Mr.
W. E. Williamson, Clerk, House Interstate and Foreign Commerce
Committee, with enclosures-"Histroical Aspects of Cannabis Sativa
in Western Medicine" and "Cannabis Substitution as an Adjunctive
Therapeutic Tool in the Treatment of Alcoholism".
Mink, Hon. Patsy T., a Representative in Congress from the State
of Hawaii:

Memorandums from Herbert H. Rozoff Associates Inc., Chicago,
Ill., for Testor Corp., Rockford, Ill., re solvent inhalation
(glue sniffing).

"Study sees glue sniffing as worse than pot"-by Gerry Keir.. National Association of Chain Drug Stores, Robert J. Bolger, executive vice president, statement

National Association of Retired Civil Employees, Thomas G. Walters, president, statement..

Page

94

712

391

395

388

400

804

814

221

219

797

814

New York Academy of Medicine, John L. Pool, M.D., president, letter dated March 13, 1970, to Chairman Jarman, with attach

825

ments_

Nix, J. T., M.D., Ph. D., medical research director Nix Foundation for Medical Research and member, Louisiana Narcotics Rehabilitation Commission, letter dated March 23, 1970, to Representative Hale Boggs, with forwarding letter to Chairman Staggers.. O'Donnell, John A., University of Kentucky, Department of Sociology and Rural Sociology, letter dated Febraury 13, 1970, to Congressman Watts of Kentucky, with forwarding letter to Chairman Staggers--

Pepper, Hon. Claude, a Representative in Congress from the State of Florida:

Amendment No. 451 to S. 3246_

800

830

591

"Crime in America-Why 8 Billion Amphetamines?", hearings
before the Select Committee on Crime, House of Representa-
tatives, November 18, 1969_ _ _ .

595

657

585

469

Federal-State cooperation in drug abuse enforcement...
Inquiries and summary of responses re amphetamines.
Pharmaceutical Manufacturers Association, suggested amendments
to H.R. 13743_.

Salk Institute, Joseph E. Slater, president, and Jacob Bronowski, Di-
rector, Council for Biology in Human Affairs, statement with at-
tachments___

Sargent, Thornton, III, Ph. D., Berkelye, Calif., letter dated February
4, 1970, to Chairman Staggers..
Tedeschi, David H., Ph. D., neuropharmacologist, Mt. Kisco, N. Y.,
letter dated March 12, 1970, to Chairman Staggers, with paper
attached entitled "Pending Drug Abuse Legislation: A Summary
and Analysis".

Wisconsin Department of Health and Social Services, Arnold M.
Ludwig, M.D., director of education and research, Division of
Mental Hygiene, Mendota State Hospital, letter dated March 9,
1970, to Representative Clement J. Żablocki of Wisconsin.............

853

836

849

751

« iepriekšējāTurpināt »